The fibrosis-cell death axis in heart failure
暂无分享,去创建一个
R. D. de Boer | H. Silljé | R. A. Boer | A. Piek | R. A. de Boer | H. H. W. Silljé | A. Piek | Herman H. W. Silljé
[1] G. Dorn. Nix Nought Nothing: fairy tale or real deal. , 2011, Journal of molecular and cellular cardiology.
[2] T. Borg,et al. Structural and functional characterisation of cardiac fibroblasts. , 2005, Cardiovascular research.
[3] J. Molkentin,et al. Molecular basis of physiological heart growth: fundamental concepts and new players , 2012, Nature Reviews Molecular Cell Biology.
[4] B. Hinz,et al. Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. , 2001, Molecular biology of the cell.
[5] Gary R. Grotendorst,et al. Combinatorial signaling pathways determine fibroblast proliferation and myofibroblast differentiation , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[6] P. Dijke,et al. Extracellular control of TGFβ signalling in vascular development and disease , 2007, Nature Reviews Molecular Cell Biology.
[7] Katherine E Yutzey,et al. Development of heart valve leaflets and supporting apparatus in chicken and mouse embryos , 2004, Developmental dynamics : an official publication of the American Association of Anatomists.
[8] R. Belardinelli,et al. Waltz Dancing in Patients With Chronic Heart Failure: New Form of Exercise Training , 2008, Circulation. Heart failure.
[9] Transforming growth factor-β: governing the transition from inflammation to fibrosis in heart failure with preserved left ventricular function. , 2011, Circulation. Heart failure.
[10] R. Hajjar,et al. Targeting sarcoplasmic reticulum calcium ATPase by gene therapy. , 2013, Human gene therapy.
[11] J. S. Janicki,et al. Interleukin 6 Mediates Myocardial Fibrosis, Concentric Hypertrophy, and Diastolic Dysfunction in Rats , 2010, Hypertension.
[12] E. McCall,et al. Cardiac Sodium Channels as Targets for New Inotropic Agents , 1998, Heart Failure Reviews.
[13] B. Hinz,et al. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. , 2012, The American journal of pathology.
[14] E. Agapitos,et al. Depressed coronary flow reserve is associated with decreased myocardial capillary density in patients with heart failure due to idiopathic dilated cardiomyopathy. , 2008, Journal of the American College of Cardiology.
[15] Hans L Hillege,et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction , 2010, Annals of medicine.
[16] T. Doetschman,et al. Fibroblast Growth Factor 2 Mediates Isoproterenol-induced Cardiac Hypertrophy through Activation of the Extracellular Regulated Kinase. , 2010, Molecular and cellular pharmacology.
[17] A. Wu,et al. High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure , 2011, Circulation. Heart failure.
[18] Who did what? , 2004 .
[19] A. Voors,et al. Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure , 2016, Expert opinion on investigational drugs.
[20] O. Frazier,et al. Fibrosis and heart failure , 2014, Heart Failure Reviews.
[21] J. McMullen,et al. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. , 2010, Pharmacology & therapeutics.
[22] A. Desmoulière,et al. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts , 1993, The Journal of cell biology.
[23] E. B. Smith. Quantitative and qualitative comparison of the lipids in platelets, aortic intima, and mural thrombi. , 1967, Cardiovascular research.
[24] D. Rifkin. Latent transforming growth factor-beta (TGF-beta) binding proteins: orchestrators of TGF-beta availability. , 2005, The Journal of biological chemistry.
[25] C. Long,et al. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. , 2005, Annual review of pharmacology and toxicology.
[26] P. Hordijk. Localizing cellular housekeeping , 2011, Nature Reviews Molecular Cell Biology.
[27] Ivan C. Gerling,et al. Myofibroblast-mediated mechanisms of pathological remodelling of the heart , 2013, Nature Reviews Cardiology.
[28] S. Kauppinen,et al. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. , 2010, The Journal of clinical investigation.
[29] Douglas E. Vaughan,et al. MiR-125b Is Critical for Fibroblast-to-Myofibroblast Transition and Cardiac Fibrosis , 2016, Circulation.
[30] M. Yacoub,et al. Functional crosstalk between cardiac fibroblasts and adult cardiomyocytes by soluble mediators. , 2015, Cardiovascular research.
[31] J. Schaper,et al. Progression From Compensated Hypertrophy to Failure in the Pressure-Overloaded Human Heart: Structural Deterioration and Compensatory Mechanisms , 2003, Circulation.
[32] M. Hori,et al. Targeted deletion of apoptosis signal-regulating kinase 1 attenuates left ventricular remodeling , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[33] W. Rottbauer,et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts , 2008, Nature.
[34] Bertram Pitt,et al. Genetic and Pharmacological Inhibition of Galectin-3 Prevents Cardiac Remodeling by Interfering With Myocardial Fibrogenesis , 2013, Circulation. Heart failure.
[35] A. Desmoulière,et al. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. , 1995, The American journal of pathology.
[36] G. Mancia,et al. Effects of cardiac denervation on blood pressure and heart rate during natural sleep in the cat. , 1968, Cardiovascular research.
[37] S. Rohr,et al. Abolishing Myofibroblast Arrhythmogeneicity by Pharmacological Ablation of &agr;-Smooth Muscle Actin Containing Stress Fibers , 2011, Circulation research.
[38] J. Goergen,et al. The collagen receptor DDR2 regulates proliferation and its elimination leads to dwarfism , 2001, EMBO reports.
[39] Zoltan Szalay,et al. Structural correlate of atrial fibrillation in human patients. , 2002, Cardiovascular research.
[40] D. Fukai,et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. , 1998, Journal of the American College of Cardiology.
[41] P. Liton,et al. Cathepsin B Is Up-Regulated and Mediates Extracellular Matrix Degradation in Trabecular Meshwork Cells Following Phagocytic Challenge , 2013, PloS one.
[42] M. Anderton,et al. Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors , 2011, Toxicologic pathology.
[43] E. Feigl,et al. Fibroblast growth factor-2 regulates myocardial infarct repair: effects on cell proliferation, scar contraction, and ventricular function. , 2007, The American journal of pathology.
[44] Hui-Hua Li,et al. Macrophage-Stimulated Cardiac Fibroblast Production of IL-6 Is Essential for TGF β/Smad Activation and Cardiac Fibrosis Induced by Angiotensin II , 2012, PloS one.
[45] M. Hori,et al. Progression of heart failure was suppressed by inhibition of apoptosis signal-regulating kinase 1 via transcoronary gene transfer. , 2007, Journal of the American College of Cardiology.
[46] Jeffrey E. Thatcher,et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis , 2008, Proceedings of the National Academy of Sciences.
[47] J. Guerrero,et al. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[48] Juerg Schwitter,et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.
[49] Z. Werb,et al. Remodelling the extracellular matrix in development and disease , 2014, Nature Reviews Molecular Cell Biology.
[50] J Michael DiMaio,et al. Making steady progress on direct cardiac reprogramming toward clinical application. , 2013, Circulation research.
[51] G. Kung,et al. Programmed necrosis, not apoptosis, in the heart. , 2011, Circulation research.
[52] G. Gabbiani,et al. The myofibroblast in wound healing and fibrocontractive diseases , 2003, The Journal of pathology.
[53] N. Turner. Effects of interleukin-1 on cardiac fibroblast function: relevance to post-myocardial infarction remodelling. , 2014, Vascular pharmacology.
[54] M. Dvoráková,et al. Effective myofibroblast dedifferentiation by concomitant inhibition of TGF-β signaling and perturbation of MAPK signaling. , 2013, European journal of cell biology.
[55] R. D. de Boer,et al. Identification of hypertrophy- and heart failure-associated genes by combining in vitro and in vivo models. , 2012, Physiological genomics.
[56] J. Teerlink. A novel approach to improve cardiac performance: cardiac myosin activators , 2009, Heart Failure Reviews.
[57] R. Kalluri,et al. Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis. , 2013, American journal of physiology. Cell physiology.
[58] J. Erler,et al. Matrix cross-linking lysyl oxidases are induced in response to myocardial infarction and promote cardiac dysfunction. , 2016, Cardiovascular research.
[59] M. Drazner,et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.
[60] N. Frangogiannis,et al. The role of IL-1 in the pathogenesis of heart disease , 2009, Archivum Immunologiae et Therapiae Experimentalis.
[61] V. Weaver,et al. Extracellular matrix assembly: a multiscale deconstruction , 2014, Nature Reviews Molecular Cell Biology.
[62] Y. Pinto,et al. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. , 2011, Cardiovascular research.
[63] J. Molkentin,et al. ASK1 Regulates Cardiomyocyte Death but Not Hypertrophy in Transgenic Mice , 2009, Circulation research.
[64] J. Horowitz,et al. Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. , 2006, Proceedings of the American Thoracic Society.
[65] J. Molkentin,et al. Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. , 2010, Circulation.
[66] G. Gabbiani,et al. The cellular derivation and the life span of the myofibroblast. , 1996, Pathology, research and practice.
[67] G. Dorn,et al. Distinct Pathways Regulate Proapoptotic Nix and BNip3 in Cardiac Stress* , 2006, Journal of Biological Chemistry.
[68] K. Red-Horse,et al. Developmental Heterogeneity of Cardiac Fibroblasts Does Not Predict Pathological Proliferation and Activation , 2014, Circulation research.
[69] Xueli Yuan,et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis , 2007, Nature Medicine.
[70] D. Kaye,et al. Role of transiently altered sarcolemmal membrane permeability and basic fibroblast growth factor release in the hypertrophic response of adult rat ventricular myocytes to increased mechanical activity in vitro. , 1996, The Journal of clinical investigation.
[71] David S. Rogers,et al. Endothelin-1 and transforming growth factor-beta1 independently induce fibroblast resistance to apoptosis via AKT activation. , 2009, American Journal of Respiratory Cell and Molecular Biology.
[72] A. Nag,et al. Study of non-muscle cells of the adult mammalian heart: a fine structural analysis and distribution. , 1980, Cytobios.
[73] Joseph A. Hill,et al. Pathological Ventricular Remodeling: Mechanisms Part 1 of 2 , 2013, Circulation.
[74] Z. Werb,et al. Extracellular matrix degradation and remodeling in development and disease. , 2011, Cold Spring Harbor perspectives in biology.
[75] H. Fillit,et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.
[76] J. McMullen,et al. The athlete's heart vs. the failing heart: can signaling explain the two distinct outcomes? , 2011, Physiology.
[77] Gang Liu,et al. New Insights into the Pathogenesis and Treatment of Idiopathic Pulmonary Fibrosis , 2011, Drugs.
[78] R. Ferrari,et al. The role of TNF in cardiovascular disease. , 1999, Pharmacological research.
[79] Stephanie L. K. Bowers,et al. Cardiac Fibroblast: The Renaissance Cell , 2009, Circulation research.
[80] A. Papavassiliou,et al. The role of inflammation in heart failure: new therapeutic approaches. , 2011, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.
[81] M. Harmsen,et al. Bone marrow‐derived myofibroblasts contribute functionally to scar formation after myocardial infarction , 2008, The Journal of pathology.
[82] B. Hinz. Formation and function of the myofibroblast during tissue repair. , 2007, The Journal of investigative dermatology.
[83] Barry Greenberg,et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): A Phase 2 Trial of Intracoronary Gene Therapy of Sarcoplasmic Reticulum Ca2+-ATPase in Patients With Advanced Heart Failure , 2011, Circulation.
[84] A. Hoes,et al. Clinical epidemiology of heart failure , 2007, Heart.
[85] K. Weber,et al. Pathological Hypertrophy and Cardiac Interstitium: Fibrosis and Renin‐Angiotensin‐Aldosterone System , 1991, Circulation.
[86] F. Strutz,et al. TGF-beta 1 induces proliferation in human renal fibroblasts via induction of basic fibroblast growth factor (FGF-2). , 2001, Kidney international.
[87] Francis G Spinale,et al. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. , 2007, Physiological reviews.
[88] M. Berry,et al. Inhibition of Matrix Metalloproteinase Activity by TIMP-1 Gene Transfer Effectively Treats Ischemic Cardiomyopathy , 2004, Circulation.
[89] J. Cohn,et al. C-Reactive Protein in Heart Failure: Prognostic Value and the Effect of Valsartan , 2005, Circulation.
[90] Paul H. Huang,et al. Discoidin Domain Receptors: Unique Receptor Tyrosine Kinases in Collagen-mediated Signaling* , 2013, The Journal of Biological Chemistry.
[91] Thomas H Everett,et al. Atrial fibrosis and the mechanisms of atrial fibrillation. , 2007, Heart rhythm.
[92] Nag Ac,et al. Study of non-muscle cells of the adult mammalian heart: a fine structural analysis and distribution. , 1980 .
[93] Dean Sheppard,et al. TGF-β activation and function in immunity. , 2014, Annual review of immunology.
[94] P. Doevendans,et al. Myocyte apoptosis in heart failure. , 2005, Cardiovascular research.
[95] R. Wachter,et al. Galectin‐3 in patients with heart failure with preserved ejection fraction: results from the Aldo‐DHF trial , 2015, European journal of heart failure.
[96] Xiaohong Yan,et al. Antagonism of endothelin-1 inhibits hypoxia-induced apoptosis in cardiomyocytes. , 2008, Canadian journal of physiology and pharmacology.
[97] B. Morgan,et al. Cardiac myosin activation part 1: from concept to clinic. , 2011, Journal of molecular and cellular cardiology.
[98] Young-Jae Nam,et al. Heart repair by cardiac reprogramming , 2013, Nature Medicine.
[99] Richard T. Lee,et al. Intramyocardial Fibroblast Myocyte Communication , 2010, Circulation research.
[100] Robert H. Anderson,et al. Lineage and Morphogenetic Analysis of the Cardiac Valves , 2004, Circulation research.
[101] P. ten Dijke,et al. Regulation of endothelial cell plasticity by TGF-β , 2011, Cell and Tissue Research.
[102] C. Tschöpe,et al. Osteopontin-mediated myocardial fibrosis in heart failure: a role for lysyl oxidase? , 2013, Cardiovascular research.
[103] K. Otsu,et al. Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. , 2010, The Journal of clinical investigation.
[104] R. D. de Boer,et al. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. , 2013, European heart journal.
[105] E Sowton,et al. Effect of changes in ventricular rate on cardiac output and central pressures at rest and during exercise in patients with artificial pacemakers. , 1967, Cardiovascular research.
[106] N. Frangogiannis,et al. The pathogenesis of cardiac fibrosis , 2013, Cellular and Molecular Life Sciences.
[107] S. Elmore. Apoptosis: A Review of Programmed Cell Death , 2007, Toxicologic pathology.
[108] A. Larue,et al. Hematopoietic origin of fibroblasts/myofibroblasts: Its pathophysiologic implications. , 2006, Blood.
[109] S. Nattel,et al. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. , 2008, Journal of the American College of Cardiology.
[110] B. Bozkurt,et al. Basic mechanisms in heart failure: the cytokine hypothesis. , 1996, Journal of cardiac failure.
[111] M. Yacoub,et al. Increased expression of extracellular matrix regulators TIMP1 and MMP1 in deteriorating heart failure. , 2003, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[112] P. Parker,et al. Endothelin-1 and fibroblast growth factors stimulate the mitogen-activated protein kinase signaling cascade in cardiac myocytes. The potential role of the cascade in the integration of two signaling pathways leading to myocyte hypertrophy. , 1994, The Journal of biological chemistry.
[113] D. Brenner,et al. Resident fibroblast lineages mediate pressure overload-induced cardiac fibrosis. , 2014, The Journal of clinical investigation.
[114] F. Meijler. Atrial fibrillation: a new look at an old arrhythmia. , 1983, Journal of the American College of Cardiology.
[115] B. Dorhout,et al. Omecamtiv Mecarbil : a Novel Cardiac Myosin Activator for the Treatment of Heart Failure , 2018 .
[116] S. Hazen,et al. Plasma myeloperoxidase levels in patients with chronic heart failure. , 2006, The American journal of cardiology.
[117] P. ten Dijke,et al. Extracellular control of TGFbeta signalling in vascular development and disease. , 2007, Nature reviews. Molecular cell biology.
[118] J. Iredale,et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. , 1998, The Journal of clinical investigation.
[119] Arantxa González,et al. Circulating Biomarkers of Myocardial Fibrosis: The Need for a Reappraisal. , 2015, Journal of the American College of Cardiology.
[120] Niels Voigt,et al. Cellular and Molecular Electrophysiology of Atrial Fibrillation Initiation, Maintenance, and Progression , 2014, Circulation research.
[121] N. Frangogiannis,et al. Aging and Cardiac Fibrosis. , 2011, Aging and disease.
[122] C. Stehouwer,et al. Microvascular Dysfunction: A Potential Mechanism in the Pathogenesis of Obesity‐associated Insulin Resistance and Hypertension , 2012, Microcirculation.
[123] M. Hori,et al. Apoptosis signal-regulating kinase 1 is involved not only in apoptosis but also in non-apoptotic cardiomyocyte death. , 2005, Biochemical and biophysical research communications.
[124] S. Hazen,et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation , 2010, Nature Medicine.
[125] Biykem Bozkurt,et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.
[126] V. Petrov,et al. Reversible and irreversible differentiation of cardiac fibroblasts , 2013, Cardiovascular research.
[127] J. Januzzi,et al. Biomarkers and diagnostics in heart failure. , 2013, Biochimica et biophysica acta.
[128] Cheuk-Man Yu,et al. miR-29b as a therapeutic agent for angiotensin II-induced cardiac fibrosis by targeting TGF-β/Smad3 signaling. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[129] G. Dorn,et al. Nix-Mediated Apoptosis Links Myocardial Fibrosis, Cardiac Remodeling, and Hypertrophy Decompensation , 2008, Circulation.
[130] A. Criollo,et al. Cardiomyocyte death: mechanisms and translational implications , 2011, Cell Death and Disease.
[131] R. Körfer,et al. The structural examination of myocardial samples from patients with end-stage heart failure supported by ventricular assist devices using electron microscopy and amino acid analysis reveals low degree of reverse remodeling. , 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[132] S. Jimenez,et al. Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. , 2011, The American journal of pathology.
[133] I. Sjaastad,et al. Attenuated development of cardiac fibrosis in left ventricular pressure overload by SM16, an orally active inhibitor of ALK5. , 2014, Journal of molecular and cellular cardiology.
[134] B. Hinz,et al. Myofibroblasts and mechano-regulation of connective tissue remodelling , 2002, Nature Reviews Molecular Cell Biology.
[135] B. Ebert,et al. Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis. , 2015, Cell stem cell.
[136] Xiaoxia Qi,et al. Heart repair by reprogramming non-myocytes with cardiac transcription factors , 2012, Nature.
[137] V. Roger. Epidemiology of Heart Failure , 2013, Circulation research.
[138] T. Pedrazzini,et al. Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2. , 2001, The Journal of clinical investigation.
[139] S. Vatner,et al. Novel mechanisms for caspase inhibition protecting cardiac function with chronic pressure overload , 2012, Basic Research in Cardiology.
[140] Don C Rockey,et al. Fibrosis--a common pathway to organ injury and failure. , 2015, The New England journal of medicine.
[141] I. Komuro,et al. Pirfenidone exhibits cardioprotective effects by regulating myocardial fibrosis and vascular permeability in pressure-overloaded hearts. , 2015, American journal of physiology. Heart and circulatory physiology.
[142] Qing-Qing Wu,et al. Cathepsin B deficiency attenuates cardiac remodeling in response to pressure overload via TNF-α/ASK1/JNK pathway. , 2015, American journal of physiology. Heart and circulatory physiology.
[143] S. Friedman,et al. Modulation of cardiac fibrosis by Krüppel-like factor 6 through transcriptional control of thrombospondin 4 in cardiomyocytes. , 2015, Cardiovascular research.
[144] M. Centrella,et al. Regulation of proliferative response of cardiac fibroblasts by transforming growth factor-beta 1. , 1996, Journal of molecular and cellular cardiology.
[145] D. Rifkin. Latent Transforming Growth Factor-β (TGF-β) Binding Proteins: Orchestrators of TGF-β Availability* , 2005, Journal of Biological Chemistry.
[146] Stephan von Haehling,et al. Inflammatory mediators in chronic heart failure: an overview , 2004, Heart.
[147] W. Linke,et al. Syndecan-4 is a key determinant of collagen cross-linking and passive myocardial stiffness in the pressure-overloaded heart. , 2015, Cardiovascular research.
[148] S. Goldstein,et al. Ventricular remodelling: consequences and therapy. , 1993, European heart journal.
[149] I. V. Van Gelder,et al. Mechanisms of atrial structural changes caused by stretch occurring before and during early atrial fibrillation. , 2011, Cardiovascular research.
[150] Sander Verheule,et al. Increased Vulnerability to Atrial Fibrillation in Transgenic Mice With Selective Atrial Fibrosis Caused by Overexpression of TGF-β1 , 2004, Circulation research.
[151] Thomas Thum,et al. Noncoding RNAs and myocardial fibrosis , 2014, Nature Reviews Cardiology.